# US 2019/0167615 A1 · Metabolites for treatment and prevention of autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167615 A1
- Document ID: US20190167615A1
- Status: Published application
- Kind: A1
- Application number: 16/323,726
- Filed: 2017-08-10
- Published: 2019-06-06
- Earliest claimed: 2016-08-10
- Assignees: Monash University; Commonwealth Scientific and Industrial Research Or
- Applicants: Monash University; Commonwealth Scientific and Industrial Research Or
- Inventors: Charles REAY MACKAY; Eliana Marino MORENO; Trevor LOCKETT; Julie CLARKE; David TOPPING
- Web page: https://patentgrep.com/patent/US20190167615A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1664: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/1617)}
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to methods for treating or preventing or delaying the progression or onset of autoimmune disease, providing dietary metabolites comprising a combination of two or more short chain fatty acids, esters or salts thereof. The present invention also provides compositions for treating, preventing or delaying the progression of, or onset of autoimmune disease.

## Claims

### Claim 1

A method of preventing or delaying the onset of an autoimmune disease in an individual, the method including providing in the individual, a therapeutically effective amount of a combination of two or more short chain fatty acids, esters or salts thereof, thereby preventing or delaying the onset of the autoimmune disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual is determined to be at risk of developing an autoimmune disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the individual is determined to have autoantibodies or inflammatory markers associated with a risk of developing an autoimmune disease.

### Claim 4

A method of delaying or preventing the progression of, or treating an autoimmune disease in an individual, the method including providing in the individual, a therapeutically effective amount of a combination of two or more short chain fatty acids, esters or salts thereof, thereby treating or delaying the progression or treating the autoimmune disease.

### Claim 5

A method of reducing or treating inflammation in an individual at risk of, or having an autoimmune disease, comprising providing in the individual, a therapeutically effective amount of a combination of two or more short chain fatty acids, esters or salts thereof, thereby reducing or treating inflammation in the individual.

### Claim 6 (depends on 5)

The method of claim 5, wherein the method includes reducing the proportion of one or more pro-inflammatory cytokines in the individual.

### Claim 7 (depends on 5, 6)

The method of claim 5 or 6, wherein the method includes increasing the proportion of one or more anti-inflammatory cytokines in the individual.

### Claim 8

A method of preventing, reducing or treating autoimmunity in an individual at risk of, or having an autoimmune disease, comprising providing in the individual, a therapeutically effective amount of a combination of two or more short chain fatty acids, esters or salts thereof, thereby preventing, reducing or treating autoimmunity in the individual.

### Claim 9

The method according to any one of the preceding claims, wherein the autoimmune disease is selected from the group consisting of: type 1 diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease, caeliac disease, autoimmune hepatitis, myocarditis, lupus nephritis, multiple sclerosis or primary biliary cirrhosis.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the autoimmune disease is type 1 diabetes.

### Claim 11

The method according to any one of the preceding claims, wherein the short chain fatty acids are selected from the group consisting of butyric acid and acetic acid and propionic acid.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the combination of short chain fatty acids is butyric acid and acetic acid.

### Claim 13

The method according to any one of the preceding claims wherein the combination of short chain fatty acids is provided in the large intestine of the individual.

### Claim 14

The method according to any one of the preceding claims, wherein the combination of short chain fatty acids is provided in the individual by oral administration to the individual of a dietary agent or pharmaceutical composition including said short chain fatty acids.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the dietary agent includes a carrier molecule covalently bonded to at least one short chain fatty acid, wherein the covalent bond is resistant to degradation in the small intestine of the individual but is hydrolysable in the colon to provide free fatty acid in the colon of the individual.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the carrier is a starch.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the pharmaceutical composition is adapted for release of the short chain fatty acids into the large intestine of the individual.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the pharmaceutical composition is adapted for release of the short chain fatty acids into the colon of the individual.

### Claim 19 (depends on 17, 18)

The method according to claim 17 or 18, wherein the pharmaceutical composition is an oral dosage form including an enteric coating which is resistant to degradation in the stomach and small intestine.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the short chain fatty acids are provided in the individual by rectal administration to the individual of a pharmaceutical composition including said short chain fatty acids.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the pharmaceutical composition is a suppository.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the short chain fatty acids are provided in the individual by injection into the individual of a pharmaceutical composition including said short chain fatty acids.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the pharmaceutical composition is adapted for subcutaneous, intravenous or intraarterial injection.

### Claim 24

A dietary agent for delivery of two or more short chain fatty acids selected from acetic acid, butyric acid and propionic acid into the large intestine of an individual, the agent including a carrier covalently bonded to the short chain fatty acids by a bond that is hydrolysable in the colon of an individual, to give free fatty acid.

### Claim 25 (depends on 24)

The dietary agent according to claim 24, wherein the carrier is a carbohydrate selected from the group consisting of a starch, gum, oligosaccharide or pectin.

### Claim 26 (depends on 25)

The dietary agent of claim 25 wherein the carrier is a starch and wherein each molecule of starch is covalently bonded to at least one butyric acid and to at least one acetic molecule.

### Claim 27 (depends on 24, 25, 26)

Use of the dietary agent of any one of claims 24 to 26, in the treatment or for delaying the progression of an autoimmune disease selected from the group consisting of type 1 diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease, caeliac disease, autoimmune hepatitis, myocarditis, lupus nephritis, primary biliary cirrhosis and multiple sclerosis.

### Claim 28 (depends on 24, 25, 26)

Use of the dietary agent of any one of claims 24 to 26, for preventing or delaying the onset an autoimmune disease selected from the group consisting of type 1 diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease, caeliac disease, autoimmune hepatitis, myocarditis, lupus nephritis, primary biliary cirrhosis and multiple sclerosis.

### Claim 29

A diet for use in the treatment or for delaying the progression of type 1 diabetes in an individual, wherein the diet includes a combination of a first and a second dietary agent, the first agent including a carrier molecule covalently bonded to a butyric acid moiety, the second agent including a carrier molecule being covalently bonded to an acetic acid moiety, wherein in each agent, the moieties are bonded to the carriers by a bond that is hydrolysable in the colon of an individual, to give free butyric acid and free acetic acid.

### Claim 30

A diet for use in preventing or delaying the onset of type 1 diabetes in an individual, wherein the diet includes a combination of a first and a second dietary agent, the first agent including a carrier molecule covalently bonded to a butyric acid moiety, the second agent including a carrier molecule being covalently bonded to an acetic acid moiety, wherein in each agent, the moieties are bonded to the carriers by a bond that is hydrolysable in the colon of an individual, to give free butyric acid and free acetic acid.

### Claim 31

Use of two or more of butyric acid, acetic acid and propionic acid in the manufacture of a medicament for the treatment or prevention an autoimmune disease.

### Claim 32 (depends on 31)

The use according to claim 31 wherein the autoimmune disease is selected from the group consisting of type 1 diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease, caeliac disease, autoimmune hepatitis, myocarditis, lupus nephritis, multiple sclerosis, and primary biliary cirrhosis.

### Claim 33

A therapeutically effective amount of two or more of butyric acid, acetic acid and propionic acid for use in the treatment or prevention of an autoimmune disease selected from the group consisting of type 1 diabetes, psoriasis, rheumatoid arthritis, inflammatory bowel disease, caeliac disease, autoimmune hepatitis, myocarditis, lupus nephritis, multiple sclerosis, and primary biliary cirrhosis.

### Claim 34

A pharmaceutical composition for the treatment or for delaying the progression of an autoimmune disease, wherein the composition includes a combination of two or more of butyric acid, acetic acid, and propionic acid, esters or salts thereof and pharmaceutically acceptable excipients, wherein the two or more of butyric acid, acetic acid and propionic acid, esters or salts thereof are the active ingredients in the composition.

### Claim 35

A pharmaceutical composition for preventing or delaying the onset of an autoimmune disease, wherein the composition includes a combination of two or more of butyric acid, acetic acid, and propionic acid, esters or salts thereof and pharmaceutically acceptable excipients, wherein the two or more of butyric acid, acetic acid and propionic acid, esters or salts thereof are the active ingredients in the composition.

### Claim 36 (depends on 34, 35)

The pharmaceutical composition according to claim 34 or 35, wherein the pharmaceutical composition is adapted for oral administration.

### Claim 37 (depends on 36)

The pharmaceutical composition according to claim 36, wherein the pharmaceutical composition includes an enteric coating which is resistant to degradation in the stomach and small intestine, thereby providing for release of the short chain fatty acids into the large intestine.

### Claim 38 (depends on 34, 35)

The pharmaceutical composition according to claim 34 or 35, wherein the pharmaceutical composition is an injectable composition.

### Claim 39 (depends on 34, 35, 36, 37, 38)

The pharmaceutical composition according to any one of claims 34 to 38, including butyric acid and acetic acid, esters or salts thereof.
